Patent Landscape and Claims Analysis for US Patent 10,335,489
What Are the Core Claims of US Patent 10,335,489?
US Patent 10,335,489, issued on June 4, 2019, primarily claims innovative aspects related to a method and system for targeted therapeutic delivery using nanocarrier platforms. The patent emphasizes specific compositions and processes aimed at enhancing delivery efficiency and specificity.
Key Claims:
- Method of delivering therapeutic agents: Uses targeted nanocarriers modified with ligands specific to cell surface receptors.
- Nanocarrier composition: Consists of a core matrix encapsulating the therapeutic agent, surface-modified with ligands for receptor binding.
- Surface modification techniques: Incorporate particular chemical conjugation steps to attach ligands, ensuring stability and targeting.
- Enhanced targeting efficiency: Demonstrates improved cellular uptake and therapeutic index over non-targeted systems.
The claims are divided into independent and dependent types, with the independent claims covering the fundamental delivery system and methods, while dependent claims refine specific compositions, ligands, and delivery conditions.
How Broad Are the Claims Compared to the Field?
The claims cover a broad spectrum of nanocarrier compositions and ligand attachments. They do not specify a narrow class of nanomaterials but instead encompass various core materials such as lipids, polymers, and inorganic particles. Similarly, the ligand scope ranges from peptides and antibodies to small molecules designed for receptor engagement.
The broad claims risk overlapping with prior art referenced in the patent, particularly existing targeted nanoparticle systems like liposomes and polymeric carriers used before 2019. The specificity of the ligand conjugation chemistry provides some narrowing, but overall, the scope remains wide.
Compared to similar patents, such as US Patent 9,708,440 (assigned to Controlled Therapeutics) and US Patent 8,962,267 (assigned to Eli Lilly), claim scope for 10,335,489 is comparable in breadth but distinguishes itself through particular chemical conjugation methods and target receptor types.
What Is the Patent Landscape Surrounding This Innovation?
The patent landscape features numerous filings exploring targeted nanocarrier delivery. Key patents include:
| Patent Number |
Assignee |
Filing Year |
Claims Focus |
Relevance & Limitations |
| US 9,708,440 |
Controlled Therapeutics |
2014 |
Liposomal targeting with ligand conjugation |
Similar target, narrower carrier type |
| US 8,962,267 |
Eli Lilly |
2012 |
Polymer-based nanocarriers with receptor targeting |
Similar application, different carrier materials |
| US 10,161,027 |
Novartis |
2017 |
Small molecule ligands for targeting nanocarriers |
Different delivery approach, ligand scope |
| EP 2,850,000 |
Bayer |
2015 |
Lipid-polymer hybrid nanocarriers with targeting ligands |
Overlaps with lipid-based systems |
The patent has potential freedom to operate given its unique chemical conjugation process and specific receptor targets. Competitors frequently explore lipid and polymer systems; some, like Eli Lilly patents, cover overlapping compositions but lack the particular ligand conjugation chemistry claimed here.
How Can Patent Challenges or Invalidations Arise?
Challenges could target the novelty or inventive step of the claims:
- Prior Art Overlap: Existing targeted nanocaressential systems used before the priority date (June 4, 2019) with similar ligand conjugations might be cited.
- Obviousness: Combining known nanocarriers with established ligand attachment chemistries could be considered obvious.
- Lack of Utility or Enablement: Insufficient examples or data demonstrating improved therapeutic outcomes may weaken validity.
Patent examiners and litigants could also scrutinize whether the specific conjugation chemistry and receptor targeting are sufficiently inventive or merely incremental modifications over prior art.
How Does This Patent Fit into Commercial Strategies?
The patent covers a versatile platform technology enabling targeted delivery across various diseases, including cancer, CNS disorders, and infectious diseases. Its broad claims allow for application to multiple therapeutic agents and receptor targets, making it attractive for companies pursuing personalized medicine.
The patent's expiration date is estimated around June 4, 2039, assuming standard 20-year patent term from filing, providing long-term exclusivity.
What Are the Opportunities and Risks?
Opportunities:
- Licensing or acquisition of the patent could expand a company's targeted delivery portfolio.
- The broad claims support multiple therapeutic applications, increasing value.
- The chemistry and ligand specificity could distinguish products in competitive markets.
Risks:
- Potential patent invalidation due to prior art or obviousness.
- Overlap with existing targeted nanocarrier patents could trigger litigation or licensing disputes.
- Limited data on clinical efficacy reduces commercial appeal at present.
Key Takeaways
- US Patent 10,335,489 claims a broadly written nanocarrier targeting system focused on receptor-specific ligand conjugation.
- The claims incorporate specific conjugation chemistries, offering some narrowing against extensive prior art.
- The patent landscape is highly active, with multiple overlapping patents on nanocarriers and ligand modifications.
- Validity may depend on demonstrating the inventive step of the specific chemical conjugation process over existing targeting methods.
- Commercial viability hinges on further data demonstrating improved clinical outcomes and potential licensing or collaboration opportunities.
FAQs
1. Can the claims be challenged based on prior nanocarrier systems?
Yes. Prior art exists for targeted liposomes, polymers, and inorganic particles, which could be cited to challenge novelty or inventive step.
2. Does the patent cover all types of ligands?
It broadly covers various ligands, including peptides, antibodies, and small molecules, provided they meet the conjugation and targeting criteria.
3. What is the main differentiator of this patent?
The specific chemical processes for ligand attachment and their application to diverse nanocarrier platforms.
4. Are there comparable patents in other jurisdictions?
Yes. Similar technology exists in the EU and Asia, with jurisdiction-specific patent families, but with variations in claiming strategies.
5. How long will the patent protect the technology?
Expiry is expected around June 4, 2039, with potential extensions if applicable (e.g., patent term adjustments).
References
[1] U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,335,489.
[2] Kaneko, T., & Smith, J. (2020). Targeted nanocarriers in drug delivery: A patent review. Journal of Pharmaceutical Innovation, 15(3), 210-225.
[3] Johnson, R., et al. (2018). Overlap analysis of nanoparticle targeting patents. Patent Insights, 12(2), 43-52.
